Investors

Board of Directors

Saniona Icon blue

Chairman since 2018
 
J. Donald deBethizy (born 1950) has more than 30 years of biopharmaceutical industry experience including as an entrepreneur, CEO and board member. In addition to serving as Chairman of Saniona’s board of directors, he also currently serves as Chairman of the board of directors for Albumedix Ltd. and as a member of the board of directors for argenx N.V., Lophora ApS, Newron Pharmaceuticals SpA, Noxxon NV and Proterris, Inc. He is also a member of management (direktion) of Albumin Holding ApS and White City Consulting ApS.
 
Previously, deBethizy served as chair of Rigontec GmbH until it was sold to Merck Inc. Prior to that, he served as CEO of Santaris Pharma A/S, until its acquisition by Roche Holdings. Prior to these positions, he served he served as executive chair of the Danish biotech Contera Pharma A/S until it was sold to Bukwang Pharma Co Ltd. Before that, he served as co-founder and CEO of Targacept, Inc., which was publicly traded on Nasdaq and later sold to Catalyst Biosciences. Before founding Targacept, deBethizy served in various positions with RJ Reynolds for 15 years. He received his Ph.D. and M.Sc. in toxicology from Utah State University and a B.Sc. in biology from the University of Maryland. Additional previous board positions have included Novozymes Biopharma DK A/S, Asceneuron SA, Biosource Inc., Enbiotix Inc., LigoCyte Pharmaceuticals Inc., Serenova A/S (previously Serendex Pharmaceuticals A/S) and Targacept.
 
deBethizy is independent in relation to both Saniona and its management as well as major shareholders. He holds 12,500 shares and 217,625 warrants in the warrant program 2018/2024.

Jørgen Drejer (born 1955) is a neurobiologist with more than 30 years of experience in discovering and developing novel approaches to modulate pathways within the brain. His research has led him to found multiple companies and publish more than 75 scientific articles.
 
Drejer founded Saniona in 2011 and served as founding Chief Executive Officer until January 2020, when he assumed the role of Chief Scientific Officer. Prior to founding Saniona, he co-founded NeuroSearch A/S in 1989, holding various leadership roles including deputy CEO and head of research over a 20-year period in which NeuroSearch became a major European biotechnology company. Drejer holds a PhD in neurobiology from the University of Copenhagen.
 
Drejer currently serves as a member of the Board of Directors for Saniona and 2CureX. He has served on the Saniona board since 2014 and served as a board member of Saniona A/S since 2012. He is also a Member of the Danish Academy of Engineering Science. He previously served as a member of the Board of Directors for NeuroSearch A/S, Origio A/S, NsGene A/S, Atonomics A/S, Azign Bioscience A/S, Ellegaard Göttingen Minipigs ApS, Force Technology and Monta Biosciences A/S.
 
Drejer is not independent in relation to Saniona and its management but is independent in relation to major shareholders. He holds 2,354,711 shares in Saniona and 77,000 warrants in the warrant program 2020/2024.

Board member since 2021.


Hoffman (1965) is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership. Hoffman currently serves as President, Chief Executive Officer and Chairman of Kintara Therapeutics (Nasdaq: KTRA). He also sits on two other publicly-traded company boards (ASLAN Pharmaceuticals – Nasdaq: ASLN and Antibe Therapeutics – TSX: ATE), serving on the audit committee and as financial expert on both boards. Hoffman also serves as a board member of the Association of Bioscience Financial Officers and of FibroBiologics, Inc., a private biotechnology company. In his most recent operating role, Hoffman was Chief Financial Officer (CFO) of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed, commercial-stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. Hoffman’s career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he was a member of the founding management team and rose to become CFO, holding that position for ten years. While at Arena, he was involved in its Initial Public Offering (IPO) and financings, raising more than $1.5 billion. Hoffman was the financial lead in two Arena acquisitions, including a Swiss manufacturing facility, and he became managing director of the facility upon the closing of the transaction. Hoffman also was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020), advising the United States accounting rulemaking organizations on emerging issues and new financial guidance. As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Hoffman has served on its board of directors for 20 years. Hoffman received his BBA in accounting from St. Bonaventure University and is a licensed CPA (Inactive) in the State of California.


Hoffman is independent in relation to both Saniona and its management as well as major shareholders. He holds 0 shares and 0 warrants. 
 

Board member since 2018
 
Anna Ljung (born 1980) is CEO of Moberg Pharma AB, a publicly-traded Swedish pharmaceutical company focused on drug delivery within dermatology. In addition to serving as CEO of Moberg Pharma, she also currently serves as Chairman of OncoZenge AB, a publicly-traded Swedish pharmaceutical company, and Chairman of Moberg Derma Incentives AB.
 
Prior to becoming CEO of Moberg, Ljung served as the company’s Chief Financial Officer for 13 years, and prior to that she was CFO at Athera Biotechnologies AB and Controller for Lipopeptide AB. She also previously was an independent consultant within the field of technology licensing. Ljung received her M.Sc. in Economics and Business Administration from Stockholm School of Economics. Additional previous board positions have included MPJ OTC AB and Advantice Health AB. 
 
Ljung is independent in relation to both Saniona and its management as well as major shareholders. She holds 4,629 shares; 4,000 warrants in the warrant program 2018/2024; 4,000 warrants in the warrant program 2019/2023; and 77,000 warrants in the warrant program 2020/2024.

Board member since 2019
 
Edward Saltzman (born 1955) has more than 30 years of experience in the biopharmaceutical industry. He currently serves as chairman and member of management of Cello Health BioConsulting, previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. Cello Health BioConsulting is a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment. Prior to the acquisition, Saltzman founded and spent 24 years as president of Defined Health. He also currently serves as investment advisor to Israel Biotech Fund and previously served as a board member for Vidac Pharmaceuticals Ltd. Saltzman earned his degree from New York University.
 
Saltzman is independent in relation to both Saniona and its management as well as major shareholders. He holds 4,200 shares, 4,000 warrants in the warrant program 2019/2023 and 77,000 warrants in the warrant program 2020/2024.

Board member since 2015 (board member of Saniona A/S since 2016)
 
Carl Johan Sundberg (born 1958) is a physician and professor with extensive experience in healthcare entrepreneurship, investment and communication. He currently serves as the Chair of the Department of Learning, Informatics, Management & Ethics at the Karolinska Institutet, Stockholm. He also currently serves as a board member for Arne Ljungqvist Anti-doping Foundation AB and Medkay Konsulting AB.
Sundberg’s affiliation with Karolinska Institutet spans over 30 years and includes work in molecular and applied exercise physiology, medical innovation and bioentrepreneurship. He also cofounded and managed Karolinska Investment Fund, a EUR 60 million biomedicine venture capital fund. His communications experience includes previous working periods with Svenska Dagbladet (a large morning daily) and ABC Television, U.S. He serves in membership and advisory positions with the Royal Swedish Academy of Engineering Sciences, Swedish Professional Associations for Physical Activity, Research!Sweden and the International Olympic Committee Medical Commission. Sundberg earned his medical degree and Ph.D. from Karolinska Institutet. Previous board positions include Cobra Biologics Holding AB, Hypercure Medical AB, Karolinska Development AB and NsGene A/S.
 
Sundberg is independent in relation to both Saniona and its management as well as major shareholders. He holds 9,800 shares; 4,000 warrants in the warrant program 2018/2024; 4,000 warrants in the warrant program 2019/2023; and 77,000 warrants in the warrant program 2020/2024.